Clinical trials: Moderate to Severe Asthma
Asthma
A Study of RO5036505 in Patients With Moderate to Severe Asthma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma.
- Trial name
- NCT00967590
- Testing
- RO5036505
- Where
- 16 sites in United States, United Kingdom
- Sponsor
- Hoffmann-La Roche
Moderate to Severe Allergic Asthma
Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma
The study was designed to collect data about inadequately controlled moderate to severe allergic asthma in subjects 6 to < 12 years of age, managed in a real-world setting.
- Trial name
- NCT01362621
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 474 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week…
- Trial name
- AJAX (NCT06020014)
- Testing
- AZD4604
- Where
- 124 sites in United States, Argentina and 16 more
- Volunteers
- 339 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma
Efficacy and tolerability of the fixed combination beclometasone/formoterol in patients with moderate to severe persistent asthma.
- Trial name
- NCT00476268
- Testing
- beclomethasone/formoterol (100/6µg) pMDI, Beclometasone dipropionate 250 µg/unit dose pMDI, Formoterol powder 12 µg/unit dose
- Volunteers
- 824 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Study of HB0056 in Adult Participants With Moderate to Severe Asthma
The goal of this clinical trial is to learn if drug HB0056 works to treat severe asthma in adults. It will also learn about the safety of drugHB0056.
- Trial name
- NCT07899996
- Testing
- HB0056
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Asthma
Study of Omalizumab in Moderate to Severe Bronchial Asthma
This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.
- Trial name
- NCT00232050
- Testing
- Omalizumab
- Volunteers
- 327 people
- Sponsor
- Novartis
Asthma
A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of subcutaneously administered Xolair as add-on therapy for the treatment of subjects aged 12-75 years old…
- Trial name
- NCT00314574
- Testing
- omalizumab (Xolair), corticosteroids, long-acting beta-agonists
- Volunteers
- 850 people
- Sponsor
- Genentech, Inc.
Moderate-to-Severe Asthma
A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
This is a Prospective, Observational, Multicentre Study to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China. Sponsor by Astrazeneca Investment(China) Co., LTD.
- Trial name
- PRESENT (NCT06422663)
- Where
- 31 sites in China
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Asthma
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
Primary Objective: To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events.
- Trial name
- NCT03387852
- Testing
- SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination
- Where
- 71 sites in United States, Argentina and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi
Allergic Asthma
The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy
The primary objective is to assess the clinical effectiveness of long-term omalizumab therapy in 240 patients treated over an 8 year period in a real-life clinical setting and to compare the pre- and post-treatment clinical…
- Trial name
- The Reality (NCT01776177)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Joseph D. Diaz, MD
Asthma
Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis
Study to evaluate the bronchodilator efficacy and safety of a fixed combination of salbutamol sulfate (120 mcg) + ipratropium bromide (20mcg) (Combivent® MDI) in aerosol plus spacer in adult patients with moderate-to-severe…
- Trial name
- NCT02182700
- Testing
- salbutamol sulfate + ipratropium bromide
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma
The purpose of this study is to assess how well JNJ-95597528 works when compared to placebo in adult participants with moderate to severe asthma (long-term condition that affects the airways in your lungs).
- Trial name
- READY-BREATHE (NCT07746687)
- Testing
- JNJ-95597528
- Volunteers
- 440 people
- Sponsor
- Janssen Research & Development, LLC
Eosinophilic Asthma
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it seeks to answer are 1.
- Trial name
- NCT05985694
- Testing
- AD17002
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Asthma (Diagnosis), Pulmonary Function
Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)
This study explores a potential new treatment for adults with moderate-to-severe asthma using a drug called linvemastat, which targets an enzyme linked to lung inflammation.
- Conditions
- Asthma (Diagnosis), Pulmonary Function, Moderate-to-Severe Asthma
- Trial name
- syMMPonia (NCT07191535)
- Testing
- linvemastat
- Volunteers
- 135 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Asthma
Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)
The aim of the study is to compare the safety and efficacy of ciclesonide versus fluticasone propionate on the lung function, symptoms, use of rescue medication, and occurrence of side effects (such as candidiasis, hoarseness) in…
- Trial name
- NCT00163319
- Testing
- Ciclesonide
- Where
- 89 sites in Belgium, France and 5 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Asthma
A Study of CM310 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT05186909
- Testing
- CM310
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Keymed Biosciences Co.Ltd
Asthma
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each…
- Trial name
- RIVER-ASTHMA (NCT06033833)
- Testing
- Amlitelimab
- Where
- 68 sites in United States, Argentina and 12 more
- Volunteers
- 335 people
- Sponsor
- Sanofi
Asthma COPD
Single and Multiple Ascending Dose Study of KN-002
This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 4 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in…
- Trial name
- KN-002 (NCT05006521)
- Testing
- KN-002
- Where
- United Kingdom
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Kinaset Therapeutics Inc
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
The purpose of this study is to provide safety and tolerability, pharmacokinetics and immunogenicity data for multiple CSJ117 doses inhaled once daily compared with placebo, in adult asthma participants treated with medium or…
- Trial name
- NCT04946318
- Testing
- CSJ117
- Where
- 58 sites in United States, Argentina and 12 more
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals